Grants per year
Personal profile
Training Experience
| 1996 | Fellowship, Wayne State University |
| 1999 | Internship, Wayne State University |
| 2002 | Residency, University of Chicago Hospitals |
| 2004 | Fellowship, University of Chicago Hospitals |
Education/Academic qualification
MD, Medical Academy, Sofia, Bulgaria
… → 1991
Fingerprint
Dive into the research topics where Roumen Deltchev Balabanov is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Northwestern Multiple Sclerosis/Neuroimmunology Fellowship
National Multiple Sclerosis Society
7/1/22 → 6/30/23
Project: Research project
-
Prot #101MS329: A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching Fro
Quintiles, Inc., Biogen MA Inc.
6/14/19 → 12/1/22
Project: Research project
-
Identifying Immune Cell Surface Markers in Multiple Sclerosis and Other Autoimmune Diseases of the Nervous System
3/22/19 → 3/22/24
Project: Research project
-
Northwestern MS/Neuroimmunology fellowship proposal
National Multiple Sclerosis Society
7/1/21 → 6/30/22
Project: Research project
-
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
NOVA study investigators, Jul 2022, In: The Lancet Neurology. 21, 7, p. 608-619 12 p.Research output: Contribution to journal › Article › peer-review
3 Scopus citations -
Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study
Perumal, J., Balabanov, R., Su, R., Chang, R., Balcer, L. J., Galetta, S. L., Avila, R. L., Rutledge, D. & Fox, R. J., Sep 2022, In: CNS Drugs. 36, 9, p. 977-993 17 p.Research output: Contribution to journal › Article › peer-review
-
Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis
Burt, R. K., Han, X., Quigley, K., Helenowski, I. B. & Balabanov, R., May 2022, In: Journal of Neurology. 269, 5, p. 2513-2526 14 p.Research output: Contribution to journal › Article › peer-review
Open Access7 Scopus citations -
Repurposing the cardiac glycoside digoxin to stimulate myelin regeneration in chemically-induced and immune-mediated mouse models of multiple sclerosis
Titus, H. E., Xu, H., Robinson, A. P., Patel, P. A., Chen, Y., Fantini, D., Eaton, V., Karl, M., Garrison, E. D., Rose, I. V. L., Chiang, M. Y., Podojil, J. R., Balabanov, R., Liddelow, S. A., Miller, R. H., Popko, B. & Miller, S. D., Oct 2022, In: Glia. 70, 10, p. 1950-1970 21 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Autologous Hematopoietic Stem Cell Transplantation for Stiff-Person Spectrum Disorder: A Clinical Trial
Burt, R. K., Balabanov, R., Han, X., Quigley, K., Arnautovic, I., Helenowski, I., Rose, J. & Siddique, T., Feb 9 2021, In: Neurology. 96, 6, p. e817-e830Research output: Contribution to journal › Article › peer-review
8 Scopus citations